Physician profile
Thomas Lynch Oconnell, JR.
NPI 1710047311
$804,781.07
in general payments reported to CMS, 2019-2025
22 companies · $151K in 2025
The $151K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $105K · 2021: $62K · 2022: $122K · 2023: $97K · 2024: $113K · 2025: $151K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $286K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Travel and Lodging: $32K · Food and Beverage: $12K · Education: $71.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,242.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $32,120.00 |
| Travel and Lodging | $31,859.31 |
| Food and Beverage | $11,768.32 |
| Education | $71.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $354,953.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $230,629.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $121,825.16 | 2022-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $79,764.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,386.00 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $4,871.79 | 2019-2021 | |
| Abbott Laboratories | $602.12 | 2021-2025 | Freestyle Libre 3, Triclip |
| Dexcom, INC. | $391.11 | 2022-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $344.51 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $216.06 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $184.35 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $172.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $98.00 | 2022-2023 | Afrezza |
| Radius Health, INC. | $79.60 | 2022-2024 | Tymlos |
| Shire North American Group INC | $63.10 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $43.58 | 2022-2025 | Cequr Simplicity |
| Ancora Heart, INC. | $37.05 | 2024 | Accucinch |
| Tandem Diabetes Care, INC. | $32.26 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $30.01 | 2022-2024 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $23.29 | 2020 | |
| Ascensia Diabetes Care US INC. | $18.93 | 2024 | |
| Acella Pharmaceuticals, LLC | $14.29 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.